ACOR Acorda Therapeutics Inc.

+0.27  (+4%)
Previous Close 7.54
Open 7.58
Price To Book 0.66
Market Cap 375,657,525
Shares 48,099,555
Volume 43,879
Short Ratio
Av. Daily Volume 893,588

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Decision on Inter Partes Review (IPR) released March 10, 2017 - patents upheld.
Improve walking in patients with multiple sclerosis
Phase 1 complete. Noted November 2017 that it will not advance into a Phase 2 study by the end of 2017, as previously expected. Evaluating next steps.
Noted November 15, 2017 seven cases of sepsis, five of which were fatal. Company noted November 20, 2017 that program will be discontinued.
Parkinson’s disease (PD)
Phase 3 data released November 21, 2016 - failed to show efficacy, development to be discontinued.
Post stroke deficits
FDA Approval announced December 22, 2018.
OFF episodes of Parkinson’s disease (PD)
Phase 2 interim data were slated for 3Q 2018 - no update given to date from company.
Primary Sclerosing Cholangitis

Latest News

  1. Akari (AKTX) Eye Candidate Proves Safety in Early-Stage Study
  2. Alexion's (ALXN) Ultomiris Gets Approval in Japan for PNH
  3. Seattle Genetics, Astellas' Cancer Candidate Attains 44% ORR
  4. Emergent (EBS) Wins HHS Contract to Supply VIGIV Product
  5. Celldex Presents Data From CDX-3379 Study at ASCO, Stock Down
  6. See what the IHS Markit Score report has to say about Acorda Therapeutics Inc.
  7. Acorda Therapeutics Debuts Art Exhibition Inspired by People with Parkinson’s at the 5th World Parkinson Congress
  8. Acorda (ACOR) Down 11.3% Since Last Earnings Report: Can It Rebound?
  9. Epizyme's NDA for Tazemetostat Eyes Epithelioid Sarcoma Cure
  10. Mesoblast Starts Rolling BLA Submission for Remestemcel-L
  11. Chiasma (CHMA) Catches Eye: Stock Jumps 9.7%
  12. Fate Therapeutics (FATE) Surges: Stock Moves 6.8% Higher
  13. Wedbush Securities Senior Vice President of Equity Research Laura Chico, Ph.D. Initiates Coverage on Six Stocks in the Healthcare and BioTech Space - ACER, ACOR, ALNX, BIIB, DOVA and SAGE
  14. Acorda Therapeutics to Present at Jefferies 2019 Healthcare Conference
  15. Is Acorda Therapeutics Inc (ACOR) A Good Stock To Buy?
  16. Edited Transcript of ACOR earnings conference call or presentation 2-May-19 12:30pm GMT
  17. Acorda Therapeutics (ACOR) Q1 2019 Earnings Call Transcript
  18. Acorda (ACOR) Earnings and Revenues Beat Estimates in Q1
  19. The Daily Biotech Pulse: FDA Nod For Sanofi's Dengue Vaccine, Veracyte Offering, Biogen Reports Positive Data